Business Wire

NC-AVAYA

12.4.2021 12:02:08 CEST | Business Wire | Press release

Share
Avaya’s “Life and Work Beyond 2020” Survey Reveals Organizations Play Key Role in Individuals’ Well-Being

Avaya (NYSE: AVYA), a global leader in solutions to enhance and simplify communications and collaboration, today released the results of a new survey, “Life and Work Beyond 2020: The Change Makers,” examining how attitudes and feelings toward home and work life have changed over the last year. The Avaya survey uncovers a significant happiness gap, with only 27% of respondents saying they were happier in 2020 and 43% saying they were less happy. The survey also reveals that organizations have the power to increase well-being, with 56% saying hybrid work has the potential to improve their well-being and 79% saying that when engaging with an organization’s contact center, they expect agents to do everything possible to make them happy.

Digital transformation and the pandemic have created lasting change in how we want to work and shop. As workers, we want a hybrid work environment that offers more choice and eliminates an inflexible daily grind. As consumers, we want to interact with businesses through the channels we prefer, and we expect in-the-moment responsiveness to address our unique needs. Businesses that want to meet these changing dynamics require composable solutions that let them build the ideal communications and collaboration environment for managing distributed teams and empowering these teams to delight customers.

“Avaya’s ‘Life and Work Beyond 2020’ survey presents a compelling case that organizations today play a critical role in our well-being, both as employers and service providers,” said Simon Harrison, Chief Marketing Officer, Avaya. “The question is, how can businesses enable hybrid work while ensuring employees have the tools they need to consistently delight customers? Avaya OneCloud is a composable communication and collaboration platform that enables businesses to bridge employee and customer experiences, with fluid, seamless engagement no matter where employees are working while empowering them to quickly create and deliver memorable experiences in the moment.”

Key Takeaways from Avaya’s “Life and Work Beyond 2020” Survey

Our sources of happiness are changing – and many are less happy

According to the survey, the unsurprising top sources of decreased happiness in 2020 include the COVID-19 pandemic (82%), less face-to-face contact with others (68%) and money worries (64%). However, among the 27% of respondents whose happiness increased, the top reasons included some surprises, including flexibility in deciding where to work (62%) and more work from home & bosses trusting workers (57%).

Work needs flexibility

The desire for more work flexibility is underscored by the fact that across all respondents, 46% feel trapped in a daily routine and 43% are struggling to find the right work-life balance. Further, 56% think that hybrid work will have the potential to improve their well-being, and 60% would support government policies that embrace hybrid working.

Changed values are reshaping how we shop

Honesty, respect and optimism are now top values, and 69% of respondents say they actively (33%) or sometimes (36%) choose organizations, including banks, retailers, utilities, healthcare providers, and telecom providers, that reflect their values. More than 1 out of 2 prefer a mix of ways to contact organizations, including a phone number on every webpage or app (69%) and more help available on websites (57%). Nearly half of respondents (47%) say convenience is more important than price.

Organizations have a big impact on our well-being

The impact of organizations on well-being is huge, with 71% of respondents saying customer service problems cause them a great deal (28%) or a considerable amount (43%) of stress. A full 79% expect organization contact centers to do everything possible to make them a happy customer, but only 13% say organizations always make them feel good after an interaction and only 8% say they are regularly delighted by their interactions.

The survey, conducted in November 2020, is based on interviews with 10,000 consumers and workers in a variety of markets around the world, including Austria, Canada, Egypt, France, Germany, India, Saudi Arabia, Switzerland, UAE, the UK and the U.S.

Additional Resources

About Avaya

Businesses are built by the experiences they provide, and everyday millions of those experiences are delivered by Avaya Holdings Corp. (NYSE: AVYA). Avaya is shaping what's next for the future of work, with innovation and partnerships that deliver game-changing business benefits. Our cloud communications solutions and multi-cloud application ecosystem power personalized, intelligent, and effortless customer and employee experiences to help achieve strategic ambitions and desired outcomes. Together, we are committed to help grow your business by delivering Experiences that Matter. Learn more at http://www.avaya.com/

Cautionary Note Regarding Forward-Looking Statements

This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) available at www.sec.gov , and may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this press release may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

All trademarks identified by ®, TM, or SM are registered marks, trademarks, and service marks, respectively, of Avaya Inc. All other trademarks are the property of their respective owners.

Source: Avaya Newsroom

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye